Results follow recent updates to ProMIS
antibody programs selectively targeting root cause of multiple
neurodegenerative diseases
TORONTO and CAMBRIDGE, MA, Oct. 23,
2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN)
(OTCQB: ARFXF), a biotechnology company focused on the discovery
and development of antibody therapeutics targeting toxic oligomers
implicated in the development of neurodegenerative diseases, has
generated antibody candidates targeting the neurotoxic form of TAR
DNA-binding protein 43 (TDP-43), a protein found in all cells and
implicated as a root cause in a spectrum of diseases such as
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia
(FTD).
New data generated by ProMIS' unique drug discovery and
development platform demonstrate that several antibody candidates
show selectivity for toxic, misfolded intracellular aggregates of
TDP-43 with no binding to normal TDP-43 located in the cell
nucleus. ProMIS antibody candidates also show selective binding to
the pathogenic, misfolded form of TDP-43 in post-mortem brain
tissue from patients with FTD.
"The momentum behind each of our programs is palpable," said
Elliot Goldstein, MD, ProMIS
Neurosciences President and CEO. "In the past 30 days, we've
announced data advancing our development programs selectively
targeting toxic misfolded proteins for treatment of Alzheimer's and
Parkinson's disease and Multiple System Atrophy (MSA), ALS and FTD.
Yesterday, Biogen's decision to submit its amyloid-beta targeting
drug candidate, aducanumab, for FDA approval signaled a
milestone shift in the promise of next-generation amyloid-beta
targeting drugs. Our lead program, PMN310, offers sniper-like
precision for the toxic, misfolded form of amyloid beta, a key
feature that offers important potential advantages compared to
aducanumab. We will continue to support the patient community by
advancing our programs, in particular PMN310 for Alzheimer's
disease, leveraging our proprietary, drug discovery platform."
To learn more about the search for therapies for Alzheimer's,
Parkinson's and other neurodegenerative diseases, listen to the
podcast, Saving Minds, at iTunes or Spotify.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines – ProMIS and Collective Coordinates – to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com, follow us
on Twitter and LinkedIn
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This
information release contains certain forward-looking information.
Such information involves known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
SOURCE ProMIS Neurosciences Inc.
